Inflammation: The next therapeutic frontier in targeting cardiovascular risk
This series consists of an introduction, three presentations and a discussion in which four experts in this field will bring you up to date on the role of inflammation in atherosclerosis and how to translate findings from science and clinical trials into practice.
1-5 of 5
- Inflammation: The next therapeutic frontier in targeting cardiovascular riskThe journey from hypothesis to reality on inflammation in CVD
Paul Ridker, MD
prof. Paul Ridker, MD
- Inflammation: The next therapeutic frontier in targeting cardiovascular riskIL-6 as therapeutic target in inflammation and CVD
Paul Ridker, MD
- Inflammation: The next therapeutic frontier in targeting cardiovascular riskInflammation and anti-inflammatory therapy in CVD
Prof. Thomas Lüscher, MD
- Inflammation: The next therapeutic frontier in targeting cardiovascular risk3 Challenges when targeting inflammation in residual CV risk
Prof. Filippo Crea, MD
- Inflammation: The next therapeutic frontier in targeting cardiovascular riskImmunity and inflammation in atherosclerosis - no longer just a theory
prof. Paul Ridker, MD
